Major R&D Pipeline: 3ADCs

Revenue Increased by 27.1 Bn JPY (Increased by 20.5 Bn JPY excl. forex impact) Daiichi-Sankyo Positive Factors (Bn JPY) Negative Factors FY2020 Results Japan Business (incl. Innovative Pharmaceuticals, Generic, Vaccines, OTC) Oncology Business*1 236.9 Japan Business Unit Lixiana +3.1 Memary -10.7 0.8 Tarlige +2.8 Enhertu +2.0 2.7 Daiichi Sankyo Espha +2.5 Ezetimibe AG, Memantine AG etc. Vaccines business Rotarix -1.5 American Regent 11.9 Daiichi Sankyo Healthcare +1.1 Roxionin EU Specialty Business 1.7 Oncology Business*1 Unit ASCA 1.7 Enhertu +5.6 Olmesartan -2.2 (Asia, South and Central America) Enhertu, Dato-DXd*2 Upfront Payment & Regulatory Milestone Forex Impact*3 American Regent Unit 1.8 Injectafer +5.2 GE injectables +5.1 6.6 FY2021 Results 264.1 EU Specialty Business Unit Lixiana +4.6 Gain on sales of transferring long-listed products -3.2 Positive Factors Negative Factors *1 Revenue for Daiichi Sankyo, Inc. and Daiichi Sankyo Europe's oncology products *2 Dato-DXd: Datopotamab deruxtecan (DS-1062) Enhertu, Dato-DXd*² Upfront Payment & Regulatory Milestone Dato-DXd upfront payment +1.5 *3 Forex impact USD: +0.9, EUR: +3.5, ASCA: +2.2 5

View entire presentation